)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AVITA Medical
AVITA Medical (RCEL) investor relations material
AVITA Medical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 revenue was $26.114M, up 53% YoY and 20% QoQ; gross margin reached 84.0% and net cash use fell to $0.6M.
Growth was led by RECELL, with Cohealyx also contributing; FY2026 revenue guidance was raised for a second consecutive quarter.
Cash flow breakeven remains expected in Q4 2026.
Financial highlights
Nine-month 2026 revenue was $67.067M, up from $53.995M; nine-month net loss narrowed to $24.5M from $37.0M.
Q3 gross profit was $21.941M; operating expenses were $24.6M, up 7% YoY and flat QoQ.
Q3 net loss narrowed to $6.222M, or $0.20 per diluted share, from $13.187M, or $0.46 per share, YoY.
Net cash use was $0.6M, versus $3.2M in Q2; September 30 cash, cash equivalents and marketable securities totaled $10.5M.
Outlook and guidance
FY2026 revenue guidance rose to $92M–$94M from $86M–$89M, implying 28%–31% growth over 2025; Q4 revenue guidance is $24.9M–$26.9M.
Cash flow breakeven remains expected in Q4 2026.
RECELL gross margin is expected to range from 86% to 90% in coming quarters; product mix may weigh on overall margin while adding gross profit.
Management expects available cash, the additional $10M credit draw and forecast revenue to fund operations for at least 12 months from issuance of the financial statements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AVITA Medical
- Operational discipline and portfolio expansion drive growth, with cash flow breakeven targeted for Q4 2026.RCEL
Morgan Stanley 24th Annual Global Healthcare Conference - PermeaDerm delivers a 70% cost reduction, workflow benefits, and clinical outcomes on par with allograft.RCELKOL event
- 2026 guidance raised to $86–$89M, with Q4 breakeven targeted and strong Q2 revenue growth.RCELInvestor update
- Revenue growth, margin stability, and product adoption drive confidence in sustained expansion.RCELCanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 revenue up 18% year-over-year; guidance raised, but going concern risk remains.RCELQ2 2026
- Sequential revenue growth, strong margins, and reaffirmed guidance signal renewed momentum.RCELStatus update
- Revenue up 4% to $19.3M, net loss narrows, but going concern risk remains.RCELQ1 2026
- 2026 guidance targets $80–$85M revenue, with growth, reimbursement clarity, and new financing.RCELStatus update
- Q2 2024 revenue up as much as 44% to $19.5M; 2024 guidance set at $68–$70M.RCELQ2 2024
Next AVITA Medical earnings date
Q4 202611 Feb, 2027
AVITA Medical
Next AVITA Medical earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AVITA Medical Inc is a regenerative medicine company that develops and markets therapeutic solutions for skin restoration. Its primary product is a spray-on skin system used for treating burns, wounds, and dermatological conditions. The company operates in North America and internationally through partnerships and direct sales. AVITA Medical Inc is headquartered in Valencia, California, and its shares are listed on the NASDAQ.